Gilead Put Profit Ahead of Hepatitis C Patients: U.S. Senate Report Says

The Senate Finance Committee has determined that the prices charged by Gilead for the Hepatitis C drugs, Sovaldi and Harvoni, do not reflect the actual research or cost incurred in producing the drugs and is officially accusing Gilead of placing profits ahead of affordability and accessibility. In 2014, Medicare and Medicaid spent more than $5 billion on Sovaldi and Harvoni. Gilead released a statement saying that with available rebates and discounts the cost is actually less expensive than that of prior treatments, and, additionally, the improved efficacy of their drugs reduce the cost of future medical complications.

To read the full Reuters article click here.

Pfizer to Buy Allergan in $160 Billion Deal

Pfizer’s announcement that it will buy Allergen (the producer of Botox) will shift the manufacturer’s headquarters to Ireland and help reduce their incurred domestic taxes by an estimated 8%. The deal will make Pfizer the largest company in the industry, as well as mark the largest instance of an international acquisition to lower a U.S.-based company’s taxes – and has earned direct criticism from President Obama, Hillary Clinton, Bernie Sanders, and Donald Trump. Both companies saw a drop in their stock prices after the announcement.

Read Reuter's article on it here.

Statins May Dampen Protective Powers of Flu Vaccines

Two new studies highlight a potential relationship between statin use and flu vaccine effectiveness in seniors; however, experts warn that studies are preliminary and the benefits of both medications outweigh any negative interactions. The findings, however, add to the list of questionable side effects of the popular cholesterol-lowering drugs, associating statin use with muscle pain, liver damage and memory loss. One study found that vaccine-recipients taking statins had 38-67% fewer flu antibodies than those not taking statins (with natural statins appearing to be less detrimental than synthetic.)  The second study more specifically identified an inflammatory interaction between statins (thought to improve cardiac health by reducing inflammation) and the vaccine (priming the body to avoid the flu through increased inflammation.) Alternatively, the reduced inflammation of statins may help fight the flu once it is infected.  These findings indicate that additional research will be needed before conclusive results can be published.

Read the article here: consumer.healthday.com

Protein Sciences Reports Flublok Vaccine Now Available Nationwide

Flublok will now be available for walk-in vaccinations at Target, Mariano’s, Roundy’s, and Brookshire’s nationwide; with the suggestion that patients call ahead to confirm availability at other pharmacies. Flublok is the only vaccine on the market that is free of formaldehyde, antibiotics, gluten, gelatin, egg protein, latex, thimerosal and other preservatives. Further, Flublok resulted in nearly 50% fewer influenza cases in older adults than an alternative egg-based influenza vaccine.

For more information, read the full news release here: www.drugstorenews.com.

DrugGoes From $13.50 a Tablet to $750, Overnight (www.nytimes.com)

Daraprim, a 62-year-old drug used to treat the life-threatening parasitic infection, toxoplasmosis, experienced a dramatic price hike after being acquired by the start up Turing Pharmaceuticals, run by former hedge fund manager Martin Shkreli. While Shkreli maintains that the cost hike will fund new research in treating toxoplasmosis and is now in line with the costs associated with treatment for other rare disease, physicians and members are not pushing for drug reformulation as the associated side effects of Daraprim can be easily managed. The price increase is in line with Shkreli’s developing reputation for questionable profit acquisition in the drug arena: in 2011, he started another company whose primary focus was acquiring old drugs and increasing their prices; prior to that, he worked to stall drug approvals made by companies whose stock he was short selling.

Shkreli is not alone in the business of, seemingly, questionable drug price hikes: this year alone, Cycloserine, a tuberculosis drug, and Isuprel and Nitropress, both heart drugs, experienced dramatic price increases after they were acquired by other drug companies. Even Daraprim’s price increased from $1 a tablet to $13.50 after it as acquired by CorePharma, prior to Turing’s acquisition this year.

Reuters.com: Kmart Pays $1.4 Million to Settle U.S. Charges Over Medicare Inducements

Kmart is accused of allowing Medicare beneficiaries to use manufacturer coupons to reduce pay and provide access to expensive brand medications instead of the preferred generic options, as well as offering gasoline discounts based on prescription volume. The practices violate the False Claims Act, which prohibits offering Medicare users benefits to influence pharmacy utilization, forcing the company to pay $1.4 million to the government to settle the suit.

Merck & Co. is entering the Hepatitis C market by targeting hard-to-treat and advanced stage patients; this approach opens up a new market space for the drug manufacturer instead of competing with Gilead Science’s Harvoni and/or Sovaldi or AbbVie Inc.’s Viekira Pak for patients in earlier stages of the disease. The advantage of Merck’s treatment beyond those currently available is its tolerance by patients with ‘substantial renal insufficiency,’ an important feature, as a large portion of patients on dialysis are Hep-C infected and no other treatment for this population exists today. Gilead is currently testing its drugs on patients with severe renal insufficiency, but is only approved for patients with mild or moderate kidney impairment (as is Viekira Pak). Merck is also investigating the additional avenue for identity by gaining approval for various subtypes of the virus: Genotypes 1, 4 and 6.  All three makers are currently working to develop a single treatment for all six subtypes of the disease.

You can learn more by reading the www.bloomberg.com article, MerckTargets Toughest Cases to Gain Hepatitis C Foothold

Script Care, Ltd. is the longest running privately held Pharmacy Benefit Manager in the industry. Since 1986, SCL has established tailored pharmacy systems for clients. We have been successful in conserving finite financial resources of our customers while at the same time consistently enhancing access to drugs through an extensive pharmacy network of over 65,500 pharmacies nationwide. Our approach, which incorporates innovative technological and clinical solutions tailored to enhance outcomes and health of clients, offers clients a low-risk, high-return option to enhance its offering and provide cost savings required to maintain and improve the viability of the program.

SCL is composed of five business lines including:

• SCL Pharmacy Benefit Management
• SCL Managed Care
• SCL Correctional Services
• SCL 340B CARE
• SCL Outsourced Business Services

SCL began operations as a PBM in 1986 and has since expanded to one of the largest privately held PBMs in the nation. At present, SCL remains a family-owned company. The combination of this consistency in management and our maintained independence has guaranteed that SCL's business ideology remains focused solely on our clients' needs.

Our integrated management and centralized business structure allows SCL to respond instantly and nimbly to changing market forces; as opposed to working new policies and procedures by means of layers of management and protocol, ideas and improvements from virtually any employment levels can be swiftly analyzed by Presidents and the CEO. This adaptability was just recently capitalized upon during the early stages of the development of the Affordable Care Act (ACA); by analyzing current operating procedures and their anticipated adherence to changing policies, SCL had the ability to respond instantly to the ACA regulations and avoid any clambering to "catch up" to industry expectations. In doing so, we removed the possibility of putting additional stress on our clients as they resolved their own ACA compliance procedures.

Lastly, not only does our structure allow for flexibility and adaptability, but our independence demands it. SCL does not have the external revenue streams that can help finance underperformance in other PBMs (ie. investors, mail order spread, drug manufacturer revenue, etc.) Instead, our effectiveness is derived entirely on the satisfaction of existing and potential clients, ensuring continuous thought innovation, market research and an authentic focus on client satisfaction. This absence of outside, investor funding additionally enables SCL to concentrate on lasting, strategic success instead of quarterly earnings figures.

Simply put, SCL's size and design creates a company that is not only proud of our capacity to offer outstanding product and services, but also one that appreciates the immediate connection that your success has on our own ongoing operations.